PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14621715

Privacy issues in second stage genomics.

J A Robertson
View original source ↗Export metadata ↓

Abstract

Research that identifies genes useful in the prevention and treatment of disease will require access to biologic samples and medical records protected by traditional notions of privacy and confidentiality. Resolving conflicts between privacy and genomic research will require articulating the ethical rules that should govern such practices and then implementing those rules in the national, regional, or local health systems in which the data of interest exists. As consensus develops about the ethical rules that should govern such research, attention will shift to the practical and political problems of installing and implementing those rules in the agencies and institutions where such research will occur.

Explore related subjects

Advisory CommitteesConfidentialityDatabases, Nucleic AcidDisclosureDuty to RecontactEthical TheoryEthics Committees, ResearchGenetic PrivacyGenetic ResearchGenomicsGuidelines as TopicHumansIcelandIndustryInformed ConsentMedical RecordsPublic PolicyResearch SubjectsRisk AssessmentTissue DonorsUnited KingdomUnited StatesAnalytical ApproachBiomedical and Behavioral ResearchGenetics and ReproductionNational Bioethics Advisory CommissiondeCode GeneticsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Robertson. 1999. Privacy issues in second stage genomics.. https://pubmed.ncbi.nlm.nih.gov/14621715/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2022

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.

Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.

Advisory Committees↗